The high specificity and sensitivity of testicular tumour markers AFP and HCG make them particularly useful in the management of these neoplasms. Basai value represents an independent prognostic variable, influencing the choice of therapy. An increase in marker level before chemotherapy may also acquire a powerful prognostic significance. The decay curve pattern is indicative of the radicality of surgery. Also during chemotherapy the behaviour of markers conditions further therapeutiG strategies.
EihornL.H., DonohueJ.P.: Cis-diamminedichloroplatinum, Vinblastine and Bleomicyne combination chemotherapy in disseminated testicular cancer. Ann. Intern. Med., 87: 293–298, 1977.
2.
DrozJ.P., KramarA., ReyA.: Prognostic factors in metastatic disease. Sem. Oncol., 19 (2): 181–189, 1992.
3.
HeskethP.J., KraneR.J.: Prognostic assessment in nonseminomatous testicular cancer: implications for therapy. J. Urol., 144: 1–9, 1990.
4.
DrozJ.P., CulineS., BironP., KramarA.: Role of prognostic factors and differing interpretations in germ-cell tumours. First International Conference on Germ Cell Tumours:25, 1994.
5.
BoslG.J., GellerN.L., CirrincioneC., NisselbaumJ., VugrinD., WhitmoreW.F., GolbeyR.B.: Serum tumour markers in patients with metastatic germ cell tumours of the testis: a 10 years experience. Am. J. Med., 75: 29–35, 1983.
6.
BartlettN.L., FreihaF.S., TortiF.M.: Serum markers in germ cell neoplasm. Hematol. Oncol. Clin. North Am., 5: 1245–1261, 1991.
7.
PicozziV.J.Jr., FreihaF.S., HanniganJ.F.Jr., TortiF.M.: Prognostic significance of a decline in serum human chorionic gonadotropin levels after initial chemotherapy for advanced germ cell carcinoma. Am. Intern. Med., 100: 183–186, 1984.
8.
PriceP., HoganS.J., HorwichA.: The growth rate of metastatic non seminomatous germ cell testicular tumour measured by marker production doubling time II: prognostic significance in patients treated by chemotherapy. Eur. J. Cancer, 26: 453–457, 1990.
9.
TonerG.C., GellerN.I., TanC., NisselbaumJ., BoslG.J.: Serum tumour marker half-life during chemotherapy allows early prediction of complete response and survival in non seminomatous germ cell tumours. Cancer Res., 50: 5904–5910, 1990.
10.
LoR.K., JohnsonD.F.: A graphical method of analyzed serum tumour marker decay in nonseminomatous testis tumours. J. Urol., 131: 896–898, 1984.
11.
BoslG.J., ChagantiR.S.K.: The use of tumour markers in germ cell malignancies. Hematol. Oncol. Clin. North Am., 8 (3): 573–587, 1994.
12.
BassettoM.A., FranceschiT., LenottiM., PariseG., PancheriF., SabbioniR., ZaninelliM., CettoG.L.: AFP and HCG in germ cell tumours. Int. J. Biol. Mark, 9 (1): 29–32, 1994.
13.
BoslG.J., GellerN.J., CirrincioneC., VogelzangN.J., KennedyR.J., WhitmoreW.F.Jr., VugrinD., ScherH., NissebaumJ., GolbeyR.B.: Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res., 43: 3403, 1983.
14.
WilliamsS.D., StableinD.M., EihornL.H., MuggiaF.M., WeissR.B., DonohueJ.P., PaulsonD.F., BrunnerK.W., JacobsE.M., SpaldingJ.T., De WysW.D., CrawfordE.D.: Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N. Engl. J. Med., 317: 1433–1438, 1987.
15.
TonerG.C., GellerN.L., LinsS.Y., BoslG.J.: Extra-gonadal and poor-risk non-seminomatous germ cell tumours. Survival and prognostic features. Cancer, 67: 2049, 1991.
16.
HorwichA., PeckhamM.J.: Transient tumour marker elevation following chemotherapy for germ cell tumours of the testis. Cancer Treat. Rep., 70: 1329, 1986.
